SYNCHRONIZE™-2: Survodutide Phase 3 trial (NCT06066528)
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 755
- actual
- Start
- 27 Nov 2023 (actual)
- Primary completion
- 12 Dec 2025 (actual)
- Sponsor
- Boehringer Ingelheim
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Survodutide 3.6 mg | Experimental | Combination Product: Survodutide | Not stated |
| Survodutide 6.0 mg | Experimental | Combination Product: Survodutide | Not stated |
| Placebo | Placebo comparator | Combination Product: Placebo | Not stated |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage change in body weight from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in body weight (kg) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in waist circumference (cm) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of Eating Behaviour patient reported outcome (PRO) | Baseline and at Week 76 |
| Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in HbA1c (mmol/mol) | Baseline and at Week 76 |
| Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg) | Baseline and at Week 76 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
SYNCHRONIZE-2 in obesity with type 2 diabetes
Adults with type 2 diabetes and a BMI of 27 or more were randomised 1:1:1 to weekly survodutide 3.6 mg, 6.0 mg or placebo.[2]
Mean weight change at week 76 was -8.2% on 3.6 mg, -9.8% on 6.0 mg and -3.9% on placebo.[2]
HbA1c changed by -0.9, -0.8 and -0.2 percentage points from a baseline of 7.4%.[2]
Gastrointestinal events occurred in 72.8%, 77.7% and 38.6% of the three groups.[2]
Sources
- 1A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
Found an error? Report a correction.